Effect of Estrogen & Stress for Postmenopausal Women
Information source: Seattle Institute for Biomedical and Clinical Research
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Aging
Intervention: Climara (Drug); Hydrocortone (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Seattle Institute for Biomedical and Clinical Research Official(s) and/or principal investigator(s): Laura D Baker, PhD, Principal Investigator, Affiliation: VA Puget Sound Health Care System & University of Washington
Summary
The study tests the hypothesis that estradiol administration exacerbates the effects of the
stress hormone cortisol on cognition and mood for postmenopausal women. This randomized,
placebo-controlled, double-blind study was designed to examine the effects of an eight-week
trial of transdermal estradiol replacement therapy (0. 10 mg/day) in combination with 4 days
of oral hydrocortisone (90 mg/day in 3 daily doses of 30 mg per dose) in the last week of
hormone therapy on cognition and mood in healthy postmenopausal women. Forty cognitively
healthy postmenopausal women were randomized to receive either placebo or estradiol skin
patches for 8 weeks. In the middle of the 7th week (day 57), subjects in each group were
again randomized to receive either a placebo tablet or an oral hydrocortisone tablet 3x/day
for 4 days. Memory testing and blood collection occurred at baseline, at week 4, and again at
week 8.
Clinical Details
Official title: Effect of Estrogen on the Stress Response for Postmenopausal Women
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Change in cognitive test scores at months 1 & 3 vs. baseline
Secondary outcome: Correlation between change in blood levels of cortisol & estradiol and cognitive scoresCorrelation between change in cognitive score and treatment-induced change in beta-amyloid
Detailed description:
Estrogen replacement has been associated with improved learning and memory in both animal and
human studies. However, there is some evidence to suggest that “stress” has a detrimental
effect on learning for female animals who still have naturally circulating estrogen.
Interestingly, when the effects of this hormone are blocked in the body, stress no longer
impairs learning. Several investigators have raised the possibility that the physiological
response to stress may be exaggerated for women compared to men. Gender differences in
biological systems that control the release of gonadal and stress hormones may explain why
estrogen is beneficial for women under nonstressed conditions, but detrimental for them under
stressed conditions. To date, no study has carefully controlled or manipulated both estrogen
use and cortisol levels to further explore this issue. In this placebo-controlled, double
blind, parallel-group design clinical study we will evaluate whether estrogen use exacerbates
stress-related impairments in cognition for healthy postmenopausal women. Forty subjects
will receive either 0. 10 mg/day of transdermal beta-estradiol or a placebo skin patch for 8
weeks. In the last week of treatment, subjects will receive 90 mg/day of oral hydrocortisone
or a placebo for 4 consecutive days. Scores on tests of memory, attention, and mood, as well
as blood levels of estrogen and cortisol will be assessed at baseline, and at weeks 4 and 8.
We predict that the estrogen+cortisol combination will have a deleterious effect on cognition
and mood relative to the effects of either hormone administered alone. The results of this
study are likely to provide important information regarding not only the nature of the
interaction between these hormonal systems that occurs in response to stress, but also the
conditions under which the beneficial effects of estrogen may be overshadowed.
Eligibility
Minimum age: 55 Years.
Maximum age: 90 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
Postmenopausal women
Exclusion Criteria:
Current HRT use Hx of DVT current steroid user Cushing's or other similar disease Breast or
uterine cancer
Locations and Contacts
Additional Information
Starting date: December 2002
Ending date: March 2005
Last updated: February 26, 2007
|